Özet
Distal malignant biliary strictures (DMBD) often originate primarily from the organs in this region [primary DMBD (p-DMBD)]. However, it can also occur with tumor metastasis [metastatic DMBD (m-DMBD)]. The purpose of this study is to compare the endoscopic palliation outcomes of patients with m-DMBD to the outcomes of patients with p-DMBD. Clinical, laboratory data, endoscopic procedures, short and long-term results of endoscopic drainage, complications, and patient prognoses of m-DMBD patients who underwent ERCP due to DMBD between November 2017 and April 2023 were examined. If the procedure was performed for palliation purposes, a metal stent was inserted, whereas if it was performed as a bridge until the result of surgery or medical treatment was expected, a metal stent or two 10 fr plastic stents were inserted. In the m-DMBD group, there were 11 patients [group 1, age: 59 (20-80) years, 6 (54.5%) females], and in the p-DMBD group, there were 15 patients [group 2, age: 66 (41-83) years, 3 (20%) females]. Group 1 included metastases from colon, lung, breast, ovary, multiple myeloma, lymphoma, sarcoma, and prostate tumors, while group 2 consisted of pancreatic and Oddi tumors. In group 1, 7 (63.6%) patients received a metal stent, and 4 (36.4%) received a plastic stent, while in group 2, these numbers were 6 (40%) and 9 (60%), respectively. Post-procedure cholangitis (0% x 0%) and the need for rescue drainage (0% x 6.7%) were similar. The 'rate of decrease' in total and direct bilirubin was similar after one week (%56 x %48, p: 0.305 and %63 x %51, p: 0.217). Stent patency time (until death, the date of the study, or the need for re-drainage) was 3 (0.5-31) months in group 1 and 5.3 (0.1-17.5) months in group 2 (p: 0.919). Re-drainage was required in 4 (36.4%) patients in group 1 and 10 (66.7%) patients in group 2 (p: 0.119). Until the date of the study or patient death, the stent did not become obstructed in 7 (63.6%) patients in group 1 and 5 (33.3%) patients in group 2. Stent patency was higher in patients with metal stents compared to those with plastic stents [6 (54.5%) x 3 (20%) for group 1 and 1 (9%) x 2 (13%) for group 2]. Endoscopic palliation in m-DMBD patients has similar efficacy and side effects to p-MBD patients. Metal stents should be preferred whenever possible.
Künye
1. Okamoto T. Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer. World Journal of Gastroenterology. 2022;28(10):985.
2. Memon N, Weinberger BI, Hegyi T, Aleksunes LM. Inherited disorders of bilirubin clearance. Pediatric research. 2016;79(3):378-86.
3. Frank BB. Clinical evaluation of jaundice: a guideline of the patient care committee of the American Gastroenterological Association. Jama. 1989;262(21):3031-4.
4. Kathpalia P, Ahn J. Assessment of jaundice in the hospitalized patient. Clinics in liver disease. 2015;19(1):155-70.
5. Berk PD, Howe RB, Bloomer JR, Berlin NI. Studies of bilirubin kinetics in normal adults. The Journal of clinical investigation. 1969;48(11):2176-90.
6. London IM, West R, Shemin D, Rittenberg D. On the origin of bile pigment in normal man. Journal of Biological Chemistry. 1950;184(1):351-8.
7. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proceedings of the National Academy of Sciences. 1968;61(2):748-55.
8. Burchell B. Purification of UDP-glucuronyltransferase from untreated rat liver. FEBS letters. 1977;78(1):101-4.
9. Gorski JP, Kasper CB. Purification and properties of microsomal UDP-glucuronosyltransferase from rat liver. Journal of Biological Chemistry. 1977;252(4):1336-43.
10. Schmid R. Direct-reacting bilirubin, bilirubin glucuronide, in serum, bile, and urine. Science. 1956;124(3211):76-7.
11. Schmid R. The identification of “direct-reacting” bilirubin as bilirubin glucuronide. Journal of Biological Chemistry. 1957;229(2):881-8.
12. Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. Journal of Pharmacology and Experimental Therapeutics. 2002;300(1):97-104.
13. Bourke E, Milne M, Stokes G. Mechanisms of renal excretion of urobilinogen. British Medical Journal. 1965;2(5477):1510.
14. Kenwright S, Levi A. Sites of competition in the selective hepatic uptake of rifamycin-SV, flavaspidic acid, bilirubin, and bromsulphthalein. Gut. 1974;15(3):220-6.
15. Schaffner F, Popper H. Capillarization of hepatic sinusoids in man. Gastroenterology. 1963;44(3):239-42.
16. Feng Y, Zhang S, Guo T, Zheng W, Wu D, Wu X, et al. Validity and safety of corticosteroids alone without biliary stenting for obstructive jaundice in autoimmune pancreatitis. Pancreatology: Official Journal of the International Association of Pancreatology (IAP)[et al]. 2020;20(8):1793-5.
17. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Annals of surgery. 1992;215(1):31.
18. Adsay NV, Andea A, Basturk O, Kilinc N, Nassar H, Cheng JD. Secondary tumors of the pancreas: an analysis of a surgical and autopsy database and review of the literature. Virchows Archiv. 2004;444:527-35.
19. Ito T, Takada R, Omoto S, Tsuda M, Masuda D, Kato H, et al. Analysis of prognostic factors in pancreatic metastases: a multicenter retrospective analysis. Pancreas. 2018;47(8):1033-9.
20. Nakamura E, Shimizu M, Itoh T, Manabe T. Secondary tumors of the pancreas: clinicopathological study of 103 autopsy cases of Japanese patients. Pathology international. 2001;51(9):686-90.
21. Akiyama H, Sato T, Toyoda S, Yamada H. An extrahepatic bile duct metastasis from a gallbladder cancer mimicking Mirizzi’s syndrome. The American journal of gastroenterology. 1999;94(2):508-10.
22. Kawakatsu S, Kaneoka Y, Maeda A, Takayama Y, Fukami Y, Onoe S. Intrapancreatic bile duct metastasis from colon cancer after resection of liver metastasis with intrabiliary growth: a case report. World Journal of Surgical Oncology. 2015;13(1):1-7.
23. Nakagawa Y, Maeda A, Seita K, Kaneoka Y. Lower bile duct metastasis from rectal cancer after surgery for liver metastasis and intrahepatic bile duct metastasis: a case report. BMC surgery. 2020;20(1):1-7.
24. Rana SS, Kapoor R, Gupta P, Gupta R. Extrahepatic biliary obstruction due to bile duct metastasis from primary esophageal squamous cell carcinoma: a rare cause of jaundice. Annals of Gastroenterology. 2019:528-.
25. Satake M, Furutani T, Ozawa H, Konishi T, Yasunaga M. A case of extrahepatic bile duct metastasis from gastric cancer. Nihon Shokakibyo Gakkai Zasshi= The Japanese Journal of Gastro-enterology. 2013;110(3):412-8.
26. Shijo M, Fukase K, Ohtsuka H, Ariake K, Masuda K, Ishida M, et al. Metastasis of ovarian cancer to the bile duct: a case report. Surgical Case Reports. 2019;5:1-6.
27. Tang J, Zhao G-X, Deng S-S, Xu M. Rare common bile duct metastasis of breast cancer: A case report and literature review. World Journal of Gastrointestinal Oncology. 2021;13(2):147.
28. Verbanck JJ, Rutgeerts LJ, Van Aelst FJ, Tytgat JH, Decoster JM, Noyez DN, et al. Primary malignant melanoma of the gallbladder, metastatic to the common bile duct. Gastroenterology. 1986;91(1):214-8.
29. Tsukada K, Takada T, Miyazaki M, Miyakawa S, Nagino M, Kondo S, et al. Diagnosis of biliary tract and ampullary carcinomas. Journal of hepato-biliary-pancreatic surgery. 2008;15:31-40.
30. Modolell I, Guarner L, Malagelada J. Vagaries of clinical presentation of pancreatic and biliary tract cancer. Annals of oncology. 1999;10:S82-S4.
31. Porta M, Fabregat X, Malats N, Guarner L, Carrato A, De Miguel A, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clinical and Translational Oncology. 2005;7:189-97.
32. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. The lancet oncology. 2003;4(3):167-76.
33. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75(S1):171-90.
34. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nature reviews Gastroenterology & hepatology. 2011;8(9):512-22.
35. Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM. Outcomes after curative resections of cholangiocarcinoma. Archives of surgery. 1993;128(8):871-8.
36. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Annals of surgery. 1996;224(4):463.
37. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise. The oncologist. 2016;21(5):594-9.
38. Brown KM, Parmar AD, Geller DA. Intrahepatic cholangiocarcinoma. Surgical Oncology Clinics. 2014;23(2):231-46.
39. van Dijkum EJ, de Wit LT, Gouma DJ, Saini S. Imaging of the hepatobiliary tract. The New England journal of medicine. 1997;337(19):1391.
40. Fritscher-Ravens A, Broering D, Knoefel W, Rogiers X, Swain P, Thonke F, et al. EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. LWW; 2004. p. 45-51.
41. Abu-Hamda EM, Baron TH, editors. Endoscopic management of cholangiocarcinoma. Seminars in liver disease; 2004: Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New ….
42. Stillman AE. Jaundice. Clinical Methods: The History, Physical, and Laboratory Examinations 3rd edition. 1990.
43. Walker HK, Hall WD, Hurst JW. Clinical methods: the history, physical, and laboratory examinations. 1990.
44. Irie H, Honda H, Shinozaki K, Yoshimitsu K, Aibe H, Nishie A, et al. MR imaging of ampullary carcinomas. Journal of computer assisted tomography. 2002;26(5):711-7.
45. Sun B, Hu B. The role of intraductal ultrasonography in pancreatobiliary diseases. Endoscopic Ultrasound. 2016;5(5):291.
46. Zhou S, Buxbaum J. Advanced Imaging of the Biliary System and Pancreas. Digestive Diseases and Sciences. 2022;67(5):1599-612.
47. Menzel J, Domschke W. Intraductal ultrasonography (IDUS) of the pancreato-biliary duct system: personal experience and review of literature. European journal of ultrasound. 1999;10(2-3):105-15.
48. Tamada K, Nagai H, Yasuda Y, Tomiyama T, Ohashi A, Wada S, et al. Transpapillary intraductal US prior to biliary drainage in the assessment of longitudinal spread of extrahepatic bile duct carcinoma. Gastrointestinal endoscopy. 2001;53(3):300-7.
49. Thomas S, Jahangir K, editors. Noninvasive imaging of the biliary system relevant to percutaneous interventions. Seminars in Interventional Radiology; 2016: Thieme Medical Publishers.
50. Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology. 2018;18(8):862-7.
51. Zhang Y, Zang M, Li J, Ji J, Zhang J, Liu X, et al. CEACAM6 promotes tumor migration, invasion, and metastasis in gastric cancer. Acta Biochim Biophys Sin. 2014;46(4):283-90.
52. Gan N, Jia L, Zheng L. A sandwich electrochemical immunosensor using magnetic DNA nanoprobes for carcinoembryonic antigen. International Journal of Molecular Sciences. 2011;12(11):7410-23.
53. Di Sena V, Thuler FPBM, Macedo EP, Paulo GAd, Della Libera E, Ferrari AP. Obstructive jaundice secondary to bile duct involvement with Hodgkin's disease: a case report. Sao Paulo Medical Journal. 2005;123:30-2.
54. Nagino M, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Kondo S, et al. Preoperative biliary drainage for biliary tract and ampullary carcinomas. Journal of hepato-biliary-pancreatic surgery. 2008;15:25-30.
55. Hatfield A, Terblanche J, Fataar S, Kernoff L, Tobias R, Girdwood A, et al. Preoperative external biliary drainage in obstructive jaundice: a prospective controlled clinical trial. The Lancet. 1982;320(8304):896-9.
56. McPherson G, Benjamin I, Hodgson H, Bowley N, Allison D, Blumgart L. Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. Journal of British Surgery. 1984;71(5):371-5.
57. Pitt HA, Gomes AS, Lois JF, Mann LL, Deutsch LS, Longmire Jr WP. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Annals of surgery. 1985;201(5):545.
58. Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, Hayakawa N, et al. Complications of hepatectomy for hilar cholangiocarcinoma. World journal of surgery. 2001;25:1277-83.
59. Anderson MA, Fisher L, Jain R, Evans JA, Appalaneni V, Ben-Menachem T, et al. Complications of ERCP. Gastrointestinal endoscopy. 2012;75(3):467-73.
60. Sharaiha RZ, Khan MA, Kamal F, Tyberg A, Tombazzi CR, Ali B, et al. Efficacy and safety of EUS-guided biliary drainage in comparison with percutaneous biliary drainage when ERCP fails: a systematic review and meta-analysis. Gastrointestinal endoscopy. 2017;85(5):904-14.
61. Paik WH, Lee TH, Park DH, Choi J-H, Kim S-O, Jang S, et al. EUS-guided biliary drainage versus ERCP for the primary palliation of malignant biliary obstruction: a multicenter randomized clinical trial. Official journal of the American College of Gastroenterology| ACG. 2018;113(7):987-97.
62. Robson P, Heffernan N, Gonen M, Thornton R, Brody L, Holmes R, et al. Prospective study of outcomes after percutaneous biliary drainage for malignant biliary obstruction. Annals of surgical oncology. 2010;17:2303-11.
63. Paik WH, Park YS, Hwang J-H, Lee SH, Yoon CJ, Kang S-G, et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointestinal endoscopy. 2009;69(1):55-62.
64. Smith A, Dowsett J, Russell R, Hatfield A, Cotton P. Randomised trial of endoscopic steriting versus surgical bypass in malignant low bileduct obstruction. The Lancet. 1994;344(8938):1655-60.
65. Speer A, Christopher R, Russell G, Hatfield AW, Macrae K, Cotton P, et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. The Lancet. 1987;330(8550):57-62.
66. Hochwald SN, Burke EC, Jarnagin WR, Fong Y, Blumgart LH. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Archives of Surgery. 1999;134(3):261-6.
67. Nagino M, Hayakawa N, Nimura Y, Dohke M, Kitagawa S. Percutaneous transhepatic biliary drainage in patients with malignant biliary obstruction of the hepatic confluence. Hepato-gastroenterology. 1992;39(4):296-300.
68. Nimura Y. Technique of inserting multiple biliary drains and management. Hepatogastroenterology. 1995;42:323-31.
69. Isayama H, Nakai Y, Kawakubo K, Kogure H, Hamada T, Togawa O, et al. Endoscopic retrograde cholangiopancreatography for distal malignant biliary stricture. Gastrointestinal Endoscopy Clinics. 2012;22(3):479-90.
70. Kahaleh M, Tokar J, Conaway MR, Brock A, Le T, Adams RB, et al. Efficacy and complications of covered Wallstents in malignant distal biliary obstruction. Gastrointestinal endoscopy. 2005;61(4):528-33.
71. Lee JH. Self-expandable metal stents for malignant distal biliary strictures. Gastrointestinal Endoscopy Clinics. 2011;21(3):463-80.
72. Taylor MC, McLeod RS, Langer B. Biliary stenting versus bypass surgery for the palliationof malignant distal bile duct obstruction: A meta-analysis. Liver Transplantation. 2000;6(3):302-8.
73. Dumonceau J-M, Tringali A, Papanikolaou IS, Blero D, Mangiavillano B, Schmidt A, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline–Updated October 2017. Endoscopy. 2018;50(09):910-30.
74. Kawashima H, Hashimoto S, Ohno E, Ishikawa T, Morishima T, Matsubara H, et al. Comparison of 8‐and 10‐mm diameter fully covered self‐expandable metal stents: A multicenter prospective study in patients with distal malignant biliary obstruction. Digestive Endoscopy. 2019;31(4):439-47.
75. Shamah S, Chapman C, Haider H, Liao C, Waxman I, Siddiqui U. Partially covered versus uncovered self-expandable metal stents: coating nor diameter affect clinical outcomes. Digestive Diseases and Sciences. 2019;64:2631-7.
76. Loew BJ, Howell DA, Sanders MK, Desilets DJ, Kortan PP, May GR, et al. Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2 diameters: final results of an international multicenter, randomized, controlled trial. Gastrointestinal endoscopy. 2009;70(3):445-53.
77. Moole H, Jaeger A, Cashman M, Volmar FH, Dhillon S, Bechtold ML, et al. Are self-expandable metal stents superior to plastic stents in palliating malignant distal biliary strictures? A meta-analysis and systematic review. medical journal armed forces india. 2017;73(1):42-8.
78. Kienbauer M, Duller C, Gschwantler M, Püspök A, Schöfl R, Kapral C. Austrian benchmarking project for ERCP: a 10-year report. Zeitschrift fur Gastroenterologie. 2018;56(10):1227-36.
79. Inamdar S, Slattery E, Bhalla R, Sejpal DV, Trindade AJ. Comparison of adverse events for endoscopic vs percutaneous biliary drainage in the treatment of malignant biliary tract obstruction in an inpatient national cohort. JAMA oncology. 2016;2(1):112-7.
80. Siddiqui A, Shahid H, Sarkar A, Cox K, Kowalski TE, Loren DE, et al. Stage of hilar cholangiocarcinoma predicts recurrence of biliary obstruction in patients with metal stents. Clinical Gastroenterology and Hepatology. 2013;11(9):1169-73.
81. Artifon EL, Sakai P, Ishioka S, Marques SB, Lino AS, Cunha JE, et al. Endoscopic sphincterotomy before deployment of covered metal stent is associated with greater complication rate: a prospective randomized control trial. Journal of clinical gastroenterology. 2008;42(7):815-9.
82. Elwir S, Sharzehi K, Veith J, Moyer MT, Dye C, McGarrity T, et al. Biliary stenting in patients with malignant biliary obstruction: comparison of double layer, plastic and metal stents. Digestive diseases and sciences. 2013;58:2088-92.
83. Liberato MJA, Canena JMT. Endoscopic stenting for hilar cholangiocarcinoma: efficacy of unilateral and bilateral placement of plastic and metal stents in a retrospective review of 480 patients. BMC gastroenterology. 2012;12(1):1-12.
84. Raju RP, Jaganmohan SR, Ross WA, Davila ML, Javle M, Raju GS, et al. Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Digestive diseases and sciences. 2011;56:1557-64.
85. Davids PH, Groen AK, Rauws E, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. The Lancet. 1992;340(8834-8835):1488-92.
86. Katsinelos P, Paikos D, Kountouras J, Chatzimavroudis G, Paroutoglou G, Moschos I, et al. Tannenbaum and metal stents in the palliative treatment of malignant distal bile duct obstruction: a comparative study of patency and cost effectiveness. Surgical Endoscopy and Other Interventional Techniques. 2006;20:1587-93.
87. Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointestinal endoscopy. 2006;63(7):986-95.
88. Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointestinal endoscopy. 2002;56(6):835-41.
89. Haag G-M, Herrmann T, Jaeger D, Stremmel W, Schemmer P, Sauer P, et al. Outcomes and risk factors for cancer patients undergoing endoscopic intervention of malignant biliary obstruction. BMC gastroenterology. 2015;15:1-7.
90. Ferraz Gonçalves JA, Rosendo E, Sousa L, Lopes AR, Leão I, Queirós R, et al. Complications of biliary drainage in patients with malignant biliary obstruction. Journal of Gastrointestinal Cancer. 2021;52:1067-72.
91. Vandenabeele LA, Dhondt E, Geboes KP, Defreyne L. Percutaneous stenting in malignant biliary obstruction caused by metastatic disease: clinical outcome and prediction of survival according to tumor type and further therapeutic options. Acta Gastro-Enterologica Belgica. 2017;80(2):249-55.
92. Yuan P, Zhang L, Li S, Li X, Wu Q. Clinical results after biliary drainage by endoscopic retrograde cholangiopancreatography for analysis of metastatic cancer survival and prognostic factors. Surgical Endoscopy. 2021;35:6220-6.
93. Takasaki Y, Irisawa A, Shibukawa G, Sato A, Abe Y, Yamabe A, et al. A case of obstructive jaundice caused by metastasis of ovarian cancer to the duodenal major papilla. Clinical Medicine Insights: Case Reports. 2018;11:1179547618791571.
94. Suzuki Y, Hoshi K, Tominaga K, Inaba Y, Yoshinaga T, Kojimahara S, et al. A case of obstructive jaundice caused by metastasis of breast cancer to the intra/extrahepatic bile duct. DEN open. 2023;3(1):e144.
95. Giestas S, Lopes S, Souto P, Agostinho C, Camacho E, Cipriano M, et al. Ampullary metastasis from breast cancer: a rare cause of obstructive jaundice. GE Portuguese Journal of Gastroenterology. 2016;23(6):300-3.
96. Lin Y, Wong SI, Wang Y, Lam C, Peng X. Periampullary Metastases from breast cancer: a case report and literature review. Case Reports in Oncological Medicine. 2019;2019.
97. Hamidu RB, Asif B, Lavu H, Kowalski T, Silver DP. Duodenal and Biliary Obstruction due to Extrinsic CompressionDuodenal and Biliary Obstruction due to Extrinsic Compression by Recurrent Lobular Breast Carcinoma: A Case Report. Case Reports in Gastroenterology. 2021;15(3):869.
98. Yoshida K, Yokoyama M, Hirao Y, Sato Y, Saito T, Soma Y, et al. Endoscopic drainage with a metallic stent for obstructive jaundice caused by bile duct metastasis of breast cancer: A case report. Clinical Case Reports. 2023;11(6).
99. Society AC. Breast cancer facts & figures 2019–2020. Am Cancer Soc. 2019:1-44.
100. Liang Y, Zhang H, Song X, Yang Q, editors. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Seminars in cancer biology; 2020: Elsevier.
101. Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer management and research. 2018:5329-38.
102. Masetti M, Zanini N, Martuzzi F, Fabbri C, Mastrangelo L, Landolfo G, et al. Analysis of prognostic factors in metastatic tumors of the pancreas: a single-center experience and review of the literature. Pancreas. 2010;39(2):135-43.
103. Okamoto T, Nakamura K, Fukuda K. Endoscopic retrograde cholangiopancreatography for bile duct obstruction due to metastatic breast cancer. Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society. 2020;32(7):1118-.
104. Bade BC, Cruz CSD. Lung cancer 2020: epidemiology, etiology, and prevention. Clinics in chest medicine. 2020;41(1):1-24.
105. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER cancer statistics review, 1975–2012. National Cancer Institute. 2014.
106. Maeno T, Satoh H, Ishikawa H, Yamashita Y, Naito T, Fujiwara M, et al. Patterns of pancreatic metastasis from lung cancer. Anticancer research. 1998;18(4B):2881-4.
107. DeLuzio MR, Moores C, Dhamija A, Wang Z, Cha C, Boffa DJ, et al. Resection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients–a systematic review. Pancreatology. 2015;15(5):456-62.
108. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87-108.
109. Inchingolo R, Nestola M, Nunes TF, Spiliopoulos S, Nardella M. Biliary involvement in liver metastases: long-term experience with biliary biopsy from a single center. Radiologia Brasileira. 2021;54:15-20.
110. Tanemura A, Mizuno S, Okura Y, Inoue H, Takaki H, Nishimura K, et al. Margin-negative limited resection of metastatic pancreatic tumors from rectal cancer preoperatively diagnosed by endoscopic ultrasound-guided fine-needle aspiration biopsies: report of two cases. Surgery today. 2014;44:366-72.
111. Riopel MA, Klimstra DS, Godellas C, Blumgart LH, Westra WH. Intrabiliary growth of metastatic colonic adenocarcinoma: a pattern of intrahepatic spread easily confused with primary neoplasia of the biliary tract. The American journal of surgical pathology. 1997;21(9):1030-6.
112. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Modern Pathology. 2000;13(9):962-72.
113. Sperti C, Moletta L, Patanè G. Metastatic tumors to the pancreas: the role of surgery. World Journal of Gastrointestinal Oncology. 2014;6(10):381.
114. Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016;122(19):2952-60.
115. Akatsu T, Shimazu M, Morii T, Morioka H, Yabe H, Kitajima M. Pancreatic metastasis from musculoskeletal sarcoma: A case report with malignant fibrous histiocytoma and review of the literature. Digestive diseases and sciences. 2007;52:1958-63.
116. Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Current treatment options in oncology. 2019;20:1-14.
117. Robert P-E, Orry D, Mor C, Rosset P, Guyetant S, Salame E, et al. Resectable pancreatic metastasis of left thighbone leiomyosarcoma: case report and literature review. Journal of gastrointestinal cancer. 2012;43:40-3.
118. Suh CH, Keraliya A, Shinagare AB, Kim KW, Ramaiya NH, Tirumani SH. Multidetector computed tomography features of pancreatic metastases from leiomyosarcoma: experience at a tertiary cancer center. World Journal of Radiology. 2016;8(3):316.
119. Huddy JR, Sodergren MH, Deguara J, Thway K, Jones RL, Mudan SS. Pancreaticoduodenectomy for the management of pancreatic or duodenal metastases from primary sarcoma. Anticancer Research. 2018;38(7):4041-6.
120. Ödemiş B, Parlak E, Başar Ö, Yüksel O, Şahin B. Biliary tract obstruction secondary to malignant lymphoma: experience at a referral center. Digestive diseases and sciences. 2007;52:2323-32.
121. Ross WA, Egwim CI, Wallace MJ, Wang M, Madoff DC, Lee JH. Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Digestive diseases and sciences. 2010;55:3271-7.
122. Fidias P, Carey RW, Grossbard ML. Non‐hodgkin's lymphoma presenting with biliary tract obstruction. A discussion of seven patients and a review of the literature. Cancer. 1995;75(7):1669-77.
123. Ito Y, Miyauchi M, Nakamura T, Takahara N, Nakai Y, Taoka K, et al. Significance of biopsy with ERCP for diagnosis of bile duct invasion of DLBCL. International journal of hematology. 2019;110:381-4.
124. Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, et al. Distant metastases in ovarian carcinoma. International Journal of Gynecologic Cancer. 2003;13(2).
125. Chan S, Wassef W. Endoscopic ultrasound-guided fine-needle aspiration for diagnosis of pancreatic metastases secondary to ovarian carcinoma. ACG Case Reports Journal. 2021;8(2).
126. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. New England Journal of Medicine. 2019;381(4):317-27.
127. Gupta A, Noba AL, Gupta S, Arora VK, Rathi V, Kumar S. Papillary cystadenocarcinoma of ovary presenting as obstructive jaundice: a rare presentation. Oman Medical Journal. 2012;27(2):159.
128. Rosenblatt M, Zafaranloo S, Tancer ML. Carcinoma of the ovary presenting as obstructive jaundice. Gynecologic oncology. 1989;32(3):385-9.
129. Ando T, Watanabe K, Mizusawa T, Sakai T, Katagiri A. Pancreatic metastasis from locally recurrent neuroendocrine differentiated prostate cancer after radical prostatectomy. Urology Case Reports. 2020;31:101155.
130. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human pathology. 2000;31(5):578-83.
131. Desai B, Elatre W, Quinn DI, Jadvar H. FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clinical nuclear medicine. 2011;36(10):961-2.
132. Jacob J, Chargari C, Bauduceau O, Fayolle M, Ceccaldi B, Prat F, et al. Pancreatic metastasis from prostate cancer. Case Reports in Medicine. 2010;2010.
133. Jang S, Stevens T, Parsi MA, Bhatt A, Kichler A, Vargo JJ. Superiority of self-expandable metallic stents over plastic stents in treatment of malignant distal biliary strictures. Clinical Gastroenterology and Hepatology. 2022;20(2):e182-e95.
